Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis

References

• LiuLZhangYLiuGLiWZhangXZanchettiAFEVER Study GroupThe Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patientsJ Hypertens200523122157217216269957
   PubMed Web of Science ®Google Scholar
• JATOS Study GroupPrincipal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS)Hypertens Res200831122115212719139601
   PubMed Web of Science ®Google Scholar
• MuramatsuTMatsushitaKYamashitaKNAGOYA HEART Study InvestigatorsComparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART StudyHypertension201259358058622232134
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSINTERHEART Study InvestigatorsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• YusufSReddySOunpuuSAnandSGlobal burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategiesCirculation2001104232855286411733407
   PubMed Web of Science ®Google Scholar
• McDowellSEColemanJJFernerRESystematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicineBMJ200633275511177118116679330
   PubMed Web of Science ®Google Scholar
• YagiHKomukaiKHashimotoKDifference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndromeJ Cardiol201055334535320350505
   PubMed Web of Science ®Google Scholar
• LawesCMRodgersABennettDAAsia Pacific Cohort Studies CollaborationBlood pressure and cardiovascular disease in the Asia Pacific regionJ Hypertens200321470771612658016
   PubMed Web of Science ®Google Scholar
• GuptaAKPoulterNRDobsonJASCOT investigatorsEthnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT TrialAm J Hypertens20102391023103020725056
   PubMed Web of Science ®Google Scholar
• ZamoranoJErdineSPaviaACRUCIAL InvestigatorsProactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trialCurr Med Res Opin201127482183321306285
   PubMed Web of Science ®Google Scholar
• WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWBPrediction of coronary heart disease using risk factor categoriesCirculation19989718183718479603539
   PubMed Web of Science ®Google Scholar
• ErdineSRoYMTseHFGemini-AALA InvestigatorsSingle-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)J Hum Hypertens200923319621018800143
   PubMed Web of Science ®Google Scholar
• Richard HobbsFDGensiniGJohn ManciniGBJEWEL Study GroupInternational open-label program to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood and lipid targets recommended by country-specific guidelines: the JEWEL programmeEur J Cardiovasc Prev Rehabil200916447248019407658
   PubMedGoogle Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA2002288232981299712479763
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRASCOT investigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• HusseinMAChapmanRHBennerJSDoes a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective studyAm J Cardiovasc Drugs201010319320220387911
   PubMed Web of Science ®Google Scholar
• SimonsLAOrtizMCalcinoGPersistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006–2010Med J Aust2011195313413721806531
   PubMed Web of Science ®Google Scholar
• ZamoranoJErdineSLopezAPCRUCIAL InvestigatorsDesign and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL studyPostgrad Med2010122271520203451
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension2003421206125214656957
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• LiuLWangJGGongLLiuGStaessenJAComparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative GroupJ Hypertens19981612 Pt 1182318299869017
   PubMed Web of Science ®Google Scholar
• LiaoJKSafety and efficacy of statins in AsiansAm J Cardiol20079941041417261409
   PubMed Web of Science ®Google Scholar
• NakamuraHArakawaKItakuraHMEGA Study GroupPrimary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trialLancet200636895421155116317011942
   PubMed Web of Science ®Google Scholar
• JamersonKDeQuattroVThe impact of ethnicity on response to antihypertensive therapyAm J Med19961013A22S32S8876472
   PubMedGoogle Scholar
• BurgesRMoiseyDUnique pharmacologic properties of amlodipineAm J Cardiol19947332A9A
   PubMed Web of Science ®Google Scholar
• MasakiYShimadaKKojimaTClinical significance of the measurements of plasma N-terminal pro-B-type natriuretic peptide levels in patients with coronary artery disease who have undergone elective drug-eluting stent implantationJ Cardiol201157330331021388786
   PubMed Web of Science ®Google Scholar
• KingHAubertREHermanWHGlobal burden of diabetes, 1995–2025: prevalence, numerical estimates, and projectionsDiabetes Care1998219141414319727886
   PubMed Web of Science ®Google Scholar
• RadhaVVimaleswaranKSBabuHNRole of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneityDiabetes Care20062951046105116644635
   PubMed Web of Science ®Google Scholar
• ChanJCMalikVJiaWDiabetes in Asia: epidemiology, risk factors, and pathophysiologyJAMA2009301202129214019470990
   PubMed Web of Science ®Google Scholar
• KenealyTElleyCRRobinsonEAn association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New ZealandDiabet Med200825111302130819046220
   PubMed Web of Science ®Google Scholar
• MenottiALantiMKromhoutDHomogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries StudyEur J Cardiovasc Prev Rehabil200815671972519050437
   PubMedGoogle Scholar
• ChoEJKimJHSutradharSYunisCWestergaadMCRUCIAL Trial InvestigatorsProactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific-Asian patients participating in the CRUCIAL trialJ Korean Med Sci201328121741174824339703
   PubMed Web of Science ®Google Scholar